Also Yaohai is very pleased to share the exciting news of a new medical breakthrough. Here, we have a finding related to mRNA family: cytokine circRNA. The unique molecule is upending the scientific understanding of cytokines in our systems by showing the key function they play in fighting disease. In the future, scientists are likely to be able to use information about this discovery to make new medicines. The evidence lies in the class of cytokine circRNA, but how does this work and what is cytokine circRNA in our body?
Cytokines are unique molecules that help form our immune system and help us to recover when we become ill. By signaling to different areas of the body, cytokines prompt it to combat infections and disease. Interleukin circRNA is a type of molecule aiding in this control over the production of cytokines. It does it by binding to what is known as a messenger RNA molecule. Specifically, the messenger RNA tells the body how to produce cytokines. These messengers and cytokine circRNAs can interact, which lead to either the termination of cytokines or regulate their production. For instance, cytokine circRNA can affect many of the fundamental processes in our bodies, including inflammation, cancer and even how we respond to drugs.
Inflammatory diseases is one of the biggest woes that many are dealing with in today. Some of these diseases are arthritis, asthma, and the inflammatory bowel disease. They happen when the immune system goes too far in attacking something that isn't actually a danger, causing damaging inflammation and agony around the body. For many people, this is extremely unfortunate and has a significant impact on their daily life.
Researchers found that a certain type of circRNA regulates inflammation. Red Fluorescent circRNA targeted control of how cytokines were made to reduce inflammation in the body. Thus able to avoid or reduce the harmful effects of inflammation. This is a significant discovery as it could open up new therapeutic strategies for inflammatory diseases. These findings demonstrate that studying cytokine circRNA can open up ways to design drugs for the inhibition of inflammation in patients with such diseases, and will eventually better their life.
The medical term cancer is very commonly known to people and millions of people around the world are suffering from it. It is known as the situation when cells in the body begin to grow abnormally and potentially cause tumors or other issues within the different parts of our body. The discovery that cytokine circRNA play a part in cancer formation could lead to a new treatment for it, and allow it to be better understood by scientists.
Biomarkers are specific molecules which can be used as signs that tell doctors how a disease is developing or if treatments are working. Scientists have discovered that one of the cytokine circRNAs levels in the body can provide an indication of whether someone has cancer, and how aggressive it is. Therefore, cytokine circRNA could be an effective biomarker used to help doctors make good decisions in treatment of cancer. A collaborative study between Chinese and Japanese scientists has discovered that changes in a type of non-coding RNA, called circRNAs, can be used to predict the prognosis of TKI-treated chronic-phase patients with CML. Understanding this information helps clinicians to adjust treatments based on the specific needs of their patients, and possibly increase the chances for better patient outcomes.
AAV Plasmid Manufacturing that might influence how well the body responds to cancer cells These molecules, by regulating how cytokines are generated, can in turn help or hinder this response. This implies that cytokine circRNA could be further exploited by scientists to enhance the immune system's attack on cancer, which would improve responses to existing immunotherapies. This is an exciting possibility that all of a sudden open up opportunities to develop better treatments, which would allow cancer patients to have significantly higher chances at survival and live healthier, more fulfilling lives.
Yaohai Bio-Pharma, a top 10 manufacturer of biological products, specializes in microbial fermentation. We have built a modern facility with robust RD capabilities and advanced equipment. We have five drug substance manufacturing lines that conform to GMP requirements for microbial fermentation and purification. We also have two automated fill-finish lines for cartridges, vials and pre-filled syringes. The fermentation scales available for use range from Cytokine circRNA to 2000L. The specifications for the filling of a vial range from 1ml up to 25ml. pre-filled syringe or cartridge filling specifications range from approximately 1-3ml. Our cGMP-compliant production facility ensures constant supply of clinical sample as well as commercial items. Our plant produces big molecules which are shipped to the globe.
Yaohai Bio-Pharma is a leading in Cytokine circRNA CDMO. Our main focus has been the production of microbial vaccinations and therapeutics to treat pets, human and veterinary health. We possess cutting-edge RD and manufacturing technology platforms that cover the entire manufacturing process from the engineering of microbial strains, to cell banking processing and method design to clinical and commercial manufacturing, making sure that we can ensure the successful delivery of the most advanced solutions. We have accumulated a huge quantity of knowledge in the bio processing microbial field. More than 200 projects have been successfully completed and we help our clients comply with regulations like those of the US FDA as well as EU EMA. We also help them to navigate Australia TGA and China NMPA. We are able to respond rapidly to market requirements and offer customized CDMO services due to our experience and expertise.
Yaohai BioPharma is a Top 10 Microbial CDMO that incorporates quality management and regulatory issues. We have developed a solid quality management system that conforms to the current GMP standards and regulations globally. Our regulatory team has an in-depth understanding of the world-wide regulatory frameworks. This allows us to accelerate biological launches. We ensure traceable production processes as well as high-quality products and in compliance with the guidelines of the US FDA and EU EMA. Cytokine circRNA and China NMPA are also satisfied. Yaohai BioPharma successfully passed an on-site audit conducted by an accredited Qualified Person of the European Union (QP) to review our GMP system and production facility. We have also been through the first certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.
Yaohai Bio-Pharma is experienced in biologicals derived from microbial sources We offer bespoke RD solutions as well as manufacturing services while minimising potential risks We have been involved in numerous modalities like subunit vaccines recombinant peptides hormones cytokines growth factors single domain antibodies enzymes plasmid DNA the mRNA and other We've specialized in several microorganisms like yeast extracellular and intracellular Cytokine circRNA (yields up to 15g/L) and intracellular soluble bacteria and inclusion body (yields as high as 10g/L) We also have the BSL-2 fermentation platform to create bacterial vaccines We focus on optimizing processes increasing product yields and reducing costs We have an efficient technology team that guarantees timely and high-quality delivery of projects This helps us bring your unique products faster to market